Purpose. To investigate linezolid-resistance mechanisms in linezolid-nonsusceptible enterococci (LNSE) isolated from a tertiary hospital in Korea. 
INTRODUCTION
In 2000, linezolid became the first member of the oxazolidinone class of antibiotics approved for clinical practice by the United States Food and Drug Administration [1] . Linezolid is indicated for treatment of multidrug-resistant Gram-positive organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci (VRE) [1] . Although linezolid-nonsusceptible (LNS) rates have not exceeded 1 % in the Linezolid Experience and Accurate Determination of Resistance and Zyvox Annual Appraisal of Potency and Spectrum programs since 2008, monitoring the emergence of linezolid-nonsusceptible enterococci (LNSE) is necessary because of increasing linezolid use [2] [3] [4] The major mechanism of linezolid resistance in enterococci is a mutation in domain V of the 23S rRNA. The G2576T substitution is the most frequent [1] . Alterations in the L3, L4 and L22 (to date only in staphylococci) ribosomal proteins are associated with decreased susceptibility to linezolid [1] . In addition to these mutations, the transferable oxazolidinone resistance gene cfr has been reported. The cfr gene encodes a methyltransferase that catalyses the post-transcriptional methylation of C-8 of nucleotide A2503 in 23S rRNA [5] . Newer transferable mechanisms of linezolid resistance such as the cfr variant gene cfr(B) have been identified in enterococci isolates [6] . The plasmid-born optrA gene for an ATP-binding cassette transporter was identified in enterococci isolates from humans and animals [7, 8] . Isolates harbouring optrA have relatively low linezolid MICs.
Investigations on the molecular characteristics of enterococcal isolates with elevated linezolid MICs are limited in Asian countries other than China. In this study, we consecutively collected LNSE for more than 4 years in a tertiary hospital in Korea and investigated the resistance mechanisms of the isolates.
METHODS
A total of 8201 enterococcal isolates (3518 Enterococcus faecium, 4151 Enterococcus faecalis and 532 other enterococcal isolates) were obtained at Samsung Medical Center, a tertiary referral hospital in South Korea, from December 2011 to May 2016. Among those, all nonduplicated LNSEs were stored in skim milk at -70 C after routine susceptibility testing, regardless of species or vancomycin-resistance phenotype.
As routine testing, identification at the species level and initial antimicrobial susceptibility testing were performed using an automated VITEK 2 system (bioM erieux, Marcy l'Etoile, France) according to the manufacturer's protocol. Isolates that showed elevated MICs for linezolid (MIC !4 mg l
À1
) were tested for linezolid susceptibility by a broth microdilution (BMD) method following Clinical and Laboratory Standards Institute (CLSI) guidelines to confirm MICs [9] . A panel for the BMD test was prepared by lyophilizing linezolid in a commercial 96-well cell culture plate (SPL Life Sciences, Pocheon, Republic of Korea). MIC interpretation was based on CLSI breakpoint criteria: 4 mg l À1 was intermediate and !8 mg l À1 was resistant [10] . E. faecalis ATCC 29212 was used as the quality control.
To investigate possible linezolid-resistance mechanisms, mutations in 23S rRNA, ribosomal proteins (L3, L4 and L22) and the presence of cfr, cfr(B) and optrA genes were investigated by PCR and bidirectional sequencing. A few primers -L22 ribosomal protein-encoding and cfr(B) genes -were designed de novo with Primer3 software (http://bioinfo.ut.ee/primer3/) from the reference enterococcus sequences (NCBI GenBank accession number NC_017960.1 for E. faecium and NC_004668.1 for E. faecalis). Primer sequences and PCR product sizes for each gene are in Table S1 (available in the online version of this article). PCR amplification of the 23S rRNA gene region was performed according to the protocol described by Prystowsky et al. [11] . Amplification conditions included denaturation at 94 C for 1 min, 34 cycles of 94 C for 1 min, 48 C for 2 min, and 72 C for 3 min, with a final extension step at 72 C for 7 min. L3-and L4-ribosomal protein-encoding genes were amplified with the following conditions: 10 min at 94 C; 35 cycles of 30 s at 94 C, 30 s at 55 C, and 1 min at 72 C; with a final extension at 72 C for 1 min [12] . For the L22 ribosomal protein-encoding gene, PCR conditions were as follows: denaturation at 94 C for 3 min, 35 cycles of 94 C for 45 s, 54 C for 45 s, and 72 C for 1 min, followed by 72 C for 10 min. The presence of cfr and optrA was identified by a previously described method (94 C for 5 min, 35 cycles of 94 C for 30 s, 55 C for 30 s, and 72 C for 1 min, followed by 72 C for 1 min) [13, 14] . For cfr(B), PCR conditions were as follows: denaturation at 94 C for 5 min, 35 cycles of 94 C for 30 s, 58 C for 30 s, and 72 C for 1 min, followed by 72 C for 5 min. An optrA-positive E. faecalis clinical isolate was used as a positive control, whereas the cfr and cfr (B) genes were synthesized by Bioneer Company (Daejeon, Republic of Korea) in a pBHA vector and were used as a positive control with each PCR run. After detection of the PCR product by gel electrophoresis followed by PCR product purification, sequencing was performed on the automated ABI Prism 3730 instrument, using a BigDye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA). The primers used for the sequencing reaction were the same as those used for PCR. For the isolates with 23S rRNA mutations, we determined the number of 23S rRNA copies mutated as described previously [15] . Nucleotides of 23S rRNA and deduced amino acid sequences of L3, L4 and L22 were compared with the reference enterococcus sequences.
Clinical information of patients was obtained through chart review. This study was approved by the Institutional Review Board of Samsung Medical Center, Seoul, Korea.
RESULTS
Prevalence and susceptibility profile of LNSE isolates A total of 298 nonduplicated enterococcal isolates were LNS on VITEK 2 analysis (Fig. S1) (Table S2) . Isolates from rectal swabs were all vancomycin-resistant, since rectal swabs were inoculated and incubated on selective chromogenic agar plates (ChromID VRE agar, bioM erieux, France) for VRE. VRE rates were 58.6 % (51/87) for LNS E. faecium and 2.1 % (1/48) for LNS E. faecalis.
Molecular mechanisms of linezolid resistance
Molecular mechanisms of linezolid resistance detected for the LNSE isolates are in Table 1 . The molecular mechanisms were identified in 28 isolates, and each isolate possessed only one resistance mechanism. Resistant mutations in domain V of the 23S rRNA gene were detected only in E. faecium [14 isolates: 71.4 % (10/14) LR and 28.6 % (4/14) LI]. All harboured a G2576T mutation. Mutated 23S rRNA copy numbers were identified as follows: one (n=3), two (n=9), three (n=1) and six (n=1) copies mutated ( Table 2 ). The isolates with only one copy mutated showed the lowest linezolid MIC (4 mg l À1 ). A total of 13 isolates, 10 E. faecalis and 3 E. faecium, contained the optrA gene. Among 10 E. faecalis with the optrA gene, 70 % (7/10) were LR and 30 % (3/10) were LI. Among three E. faecium with optrA gene, 33.3 % (1/3) was LR and the remaining 66.7 % (2/3) were LI. The majority (77.8 %, 7/9) of LR E. faecalis had the optrA gene. One LI E. faecium harboured a L22 protein alteration (Ser77Thr). No isolates contained cfr or cfr(B) genes and any L3 or L4 protein alterations. No genetic mechanism for resistance was identified in 67.6 % (23/34) of LR E. faecium and 22.2 % (2/9) of LR E. faecalis.
Clinical and microbiological characteristics of cases of LNSE with 23S rRNA mutations or optrA Characteristics of LNSE isolates with a 23S rRNA mutation or optrA gene are given in Table 2 . The majority of isolates with a G2576T mutation were resistant to linezolid (10/14), vancomycin (13/14), ampicillin (13/14), ciprofloxacin (13/ 14), erythromycin (10/14) and teicoplanin (13/14), but susceptible to tetracycline (13/14) and quinupristin-dalfopristin (13/14). The majority (10/12) of isolates with a G2576T mutation were isolated from patients with previous linezolid therapy, except for two patients whose medical history was unavailable.
Linezolid MICs for optrA-positive isolates were 4-8 mg l À1 . All three LNS E. faecium isolates with optrA were resistant to ampicillin, erythromycin and ciprofloxacin; except for one isolate, these isolates were susceptible to vancomycin and teicoplanin. All 10 LNS E. faecalis isolates with optrA were resistant to quinupristin-dalfopristin and erythromycin, but susceptible to ampicillin, vancomycin and teicoplanin. These isolates were generally resistant to ciprofloxacin (7/10) and tetracycline (8/10). No patients with optrApositive isolates received linezolid before isolation of LNSE except for one patient with E. faecium.
DISCUSSION
Linezolid is an important antibiotic for the treatment of infection by multidrug-resistant Gram-positive cocci. LNSE have emerged since linezolid was introduced into clinical practice and requires attention. In Korea, the first case in which LR E. faecium with a G2576T mutation in 23S rRNA was reported in 2006 [16] . To our knowledge, this is the largest-scale study to investigate the molecular characteristics of LNSE in Korea. We investigated all resistance mechanisms reported so far, involving mutations in domain V of 23S rRNA, alterations in ribosomal proteins (L3, L4 and L22), and the presence of cfr, cfr(B) and optrA genes. Linezolid-resistance mechanisms were found in 18 isolates from 87 LNS E. faecium isolates. Among 34 LR E. faecium isolates, mechanisms were identified only for 11 isolates. In previous studies, positive rates for 23S rRNA mutations in LR E faecium were 66.7 % (8/12 isolates) in a Canadian study [17] , 92.4 % (232/251 isolates) in a German study [18] , and 97.6 % (40/41 isolates) in a Polish study [19] . The dominant mechanism of linezolid resistance in E. faecium was a G2576T substitution in 23S rRNA, consistent with previous findings [1, [17] [18] [19] . However, in this study, molecular mechanisms for linezolid resistance were not identified in about two-thirds of LR E. faecium. Since the discovery of the optrA gene in 2015 and identification of other resistance mechanisms, LR E. faecium with unknown resistance mechanisms have been scarce in the literature [2] [3] [4] 19] . Our data suggested regional differences in linezolid-resistance mechanisms of E. faecium in Korea, compared to European and North American studies. Furthermore, the data suggested additional mechanisms that could lead to linezolid resistance in enterococci, especially in E. faecium.
In our study, optrA was the only known transferable linezolid-resistance gene in enterococci. Other nonmutational resistance mechanisms such as the presence of cfr or cfr(B) were not detected, although they have been observed in both E. faecium and E. faecalis [6, 17, 20] . The occurrence of optrA in enterococci from clinical specimens is reported mainly in China, Italy and the USA [7, 8, 14, 19, 21, 22] . However, to our knowledge, this is the first report on the presence of optrA in clinical enterococci in East Asia except China. The optrA gene was the only linezolid-resistance mechanism in LR E. faecalis and had a high occurrence (77.8 %, 7/9). Our results suggested the possibility for worldwide distribution of optrA. These results support previous studies in indicating that active surveillance for the presence of optrA in enterococci is warranted, based on potential risks for gene transfer between Enterococcus species [8, [21] [22] [23] .
Although it is assumed that variants in the gene for the L22 protein play a role in linezolid susceptibility due to its close proximity to the linezolid-binding site [24] , the ribosomal variants in L22 have been very rarely reported in staphylococci, and have not been reported in enterococci [25] . In the present study, a nonsynonymous variant, Ser77Thr, was detected in the L22 protein from one LI E. faecium, although it remains unclear whether this amino acid substitution resulted in the elevated linezolid MICs.
Our study has some limitations. It comes from a single institution and molecular typing was not performed. In addition, we could not determine the association between optrA variants and linezolid MICs, since a partial optrA gene was sequenced in the present study. Despite these limitations, we demonstrated that the dominant linezolid-resistance mechanism in E. faecalis in Korea was carriage of the optrA gene. In clinical E. faecium isolates, regional differences in the mechanism of linezolid resistance were noted. Known linezolid-resistance mechanisms were not found in most E. faecium isolates and further investigation is needed to identify additional novel mechanism(s).
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